‘Major improvement’: Divarasib extends survival in KRAS G12C-mutated NSCLC
Genentech/Roche's investigational drug divarasib showed improved overall survival and progression-free survival in KRAS G12C-mutated NSCLC patients compared to standard treatments sotorasib (Amgen) and adagrasib (Bristol Myers Squibb). The phase 3 Krascendo 1 trial results, presented at ESMO Congress, indicated a 44% lower risk of death with divarasib, along with fewer severe adverse effects.
How this was made
The 30-second read
Why it matters
The article reports statistically significant improvements in both PFS and interim OS for divarasib, alongside fewer grade 3/4 treatment-related adverse events and lower discontinuation rates due to treatment-related adverse events.
Market read
Pivotal-like phase 3 efficacy and safety differentiation versus the two current KRAS G12C standards can drive near-term repricing of oncology pipeline value and competitive positioning.
What to watch
The trial excludes patients with active/untreated CNS metastases, so real-world effectiveness versus broader KRAS G12C populations may be less certain than the headline OS/PFS figures suggest.
Background
Krascendo 1 is a randomized phase 3 trial in previously treated locally advanced or metastatic KRAS G12C-mutated NSCLC, comparing divarasib against sotorasib and adagrasib.
Ticker impact
Sotorasib (Lumakras, Amgen) is used as the control comparator, and divarasib showed a 44% lower risk of death versus sotorasib in Krascendo 1.
Likely downward pressure as the market reassesses the durability and competitiveness of sotorasib versus next-generation KRAS G12C inhibitors.
The article directly contrasts outcomes between divarasib and sotorasib, including OS HR and PFS HR, which can shift perceived efficacy leadership.
Adagrasib (Krazati, Bristol Myers Squibb) is another comparator, and divarasib improved OS and PFS versus adagrasib in Krascendo 1.
Likely downward bias as investors re-rank KRAS G12C inhibitor efficacy and safety in previously treated advanced/metastatic NSCLC.
The article provides directionally worse OS/PFS and higher grade 3/4 treatment-related adverse events for the control arms versus divarasib.
Market effects
Re-ranks next-generation KRAS G12C inhibitor competitiveness, potentially increasing investor focus on efficacy and tolerability differentiation beyond first-generation agents.
Primarily impacts US-listed biotech sentiment for oncology pipeline leadership; conference and NEJM publication can drive cross-Atlantic read-through.
KRAS G12C NSCLC is a global standard-of-care battleground, so improved survival data can influence global treatment expectations and partner/investor sentiment.
Counterpoint
OS advantage is based on interim survival analysis; investors may wait for final OS maturity and subgroup consistency before fully repricing the competitive landscape.
Key entities
- investigational drugdivarasib (GDC-6036)
Next-generation KRAS G12C-targeted therapy evaluated in Krascendo 1.
- KRAS G12C inhibitorsotorasib (Lumakras)
First-generation KRAS G12C inhibitor used as a comparator arm.
- KRAS G12C inhibitoradagrasib (Krazati)
First-generation KRAS G12C inhibitor used as a comparator arm.
- clinical trialKrascendo 1 trial
Randomized phase 3 study presented at ESMO Congress and published in NEJM.
